A Biomarker Analysis of Nivolumab in Previously Treated Advanced Gastric Cancer(WJOG10417GTR)
Not Applicable
- Conditions
- Gastric Cancer
- Registration Number
- JPRN-UMIN000032686
- Lead Sponsor
- West Japan Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1)Synchronous or metachronous malignancies 2)A positive test result for any of the followings: Human immunodeficiency virus antibody, hepatitis B surfaces (HBs) antigen, or hepatitis C virus antibody 3)Positive test result for either HBs antibody or hepatitis B core antibody, with a detectable level of hepatitis B virus-deoxyribonucleic acid (HBV-DNA) even in case of negative HBs antigen test 4)Judged to be incapable of providing consent for certain reasons, such as concurrent dementia
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To explore the factors related of efficacy of nivolumab such as response, progression free survival and overall survival
- Secondary Outcome Measures
Name Time Method To explore the mechanism of intrinsic and acquired resistance of nivolumab